Bradley L. Campbell — President and Chief Operating Officer at Amicus Therapeutics

Mr. Bradley L. Campbell, also known as Brad, has been the Chief Operating Officer of Amicus Therapeutics, Inc. since December 2013 and also its President since January 12, 2015. Mr. Campbell leads the strategy, design and execution of global commercial operations to support the launch of Galafold TM. Mr. Campbell has over 15 years of experience in the Orphan Drug industry. He served as the Chief Business Officer of Amicus Therapeutics, Inc. from February 01, 2012 to December 2013 and served as its Senior Vice President of Business Operations from January 2010 to February 2012, Vice President of Business Planning from May 2007 to January 2010 and Vice President of Business Operations until January 2010 and oversaw program management, business development and commercial planning. Mr. Campbell joined Amicus in May 2006. From April 2006 to May 2007, Mr. Campbell served as Senior Director of Business Development. From 2002 to 2006, he served as Senior Product Manager and later Business Director of CV Gene Therapy at Genzyme Corporation. He worked in sales & marketing for Bristol-Myers Squibb and as a business strategy consultant for Marakon Associates. He is active in a number of philanthropic organizations. He served as the President of the Board of Directors of the National Tay-Sachs and Allied Diseases Association. He has been a Director of Progenics Pharmaceuticals, Inc. since June 8, 2016. He has been a Trustee of BioNJ Inc. since November 3, 2015. He serves as Corporate Advisory Council member of National Tay-Sachs and Allied Diseases Association. Mr. Campbell holds a B.A. in Public Policy Studies from Duke University and an M.B.A. from Harvard Business School.